All times listed are Central Daylight Time. Program and Faculty are updated often – check back for the most up-to-date information. Click on session name to view session description and component talks.
0957: Multi-Omic Profiling Reveals a Monocyte-Vascular Signature Associated with the Regression of Skin Fibrosis in SSc
Location: Hall F1
Abstract Poster Presenter: Astrid Hofman, MSc – Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0958: Asynchronous Resolution of Inflammation and Fibrosis in a Prolonged Experimental Model Suggests Distinct Temporal Dynamics and Resolution Mechanisms in Systemic Sclerosis
0959: Longitudinal Multiomic Study of Skin, Peripheral Blood, and Serum: Serum Proteome Reflects the Disease Process at the End-organ Level and Predicts the Course of Modified Rodnan Skin Score
0960: Pharmaceutical Blockade of the Neonatal Fc Gamma Receptor Ameliorates Autoimmunity, Inflammation and Fibrosis in the Topoisomerase I Mouse Model of Systemic Sclerosis
Location: Hall F1
Abstract Poster Presenter: Cuong Tran Manh, PhD (he/him/his) – Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University.
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0961: Retinoic acid-related orphan receptor-α: A novel upstream regulator of Hippo signaling and potential therapeutic target in fibrosis
Location: Hall F1
Abstract Poster Presenter: Cuong Tran Manh, PhD (he/him/his) – Department of Rheumatology, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University. Hiller Research Center, University Hospital Düsseldorf, Medical Faculty of Heinrich-Heine University.
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0962: Spatial Proteomics Analysis of the organization of tertiary lymphoid structures in Systemic Sclerosis Skin
Location: Hall F1
Abstract Poster Presenter: Dennis Bleck, PhD (he/him/his) – University Hospital Düsseldorf, Department of Rheumatology, Hiller Research Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0964: A Single-cell Atlas Reveals Dermal Endothelial Heterogeneity and Disease-specific Pathways in Autoimmune Disorders
Location: Hall F1
Abstract Poster Presenter: Jinyi Qian, -None- – Shanghai Jiao Tong University School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0965: Inhibition of Nicotinamide N-Methyltransferase Reverses Fibroblast Activation via Epigenetic and Metabolic Remodeling in Systemic Sclerosis
0966: Integrated Bulk and Single Cell Analysis Confirms Differential Upregulation of the Proton Sensing Receptor GPR68 in Systemic Sclerosis Across Disease Stage and Subset
0973: Effects of a Novel Hybrid Protein Based on S100 on Macrophage Polarization and Its Therapeutic Efficacy in a Bleomycin-Induced Systemic Sclerosis Mouse Model.
Location: Hall F1
Abstract Poster Presenter: Takuya Kotani, MD, PhD – Osaka Medical and Pharmaceutical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0974: Tissue resident macrophages derived from induced pluripotent stem cells induce tissue fibrosis in human skin equivalent models of systemic sclerosis
Location: Hall F1
Abstract Poster Presenter: Xuezhi Hong, MD – Department of Rheumatology, University Hospital Dusseldorf, Medical Faculty of Heinrich Heine University, Dusseldorf, Germany
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0975: Linezolid prevents fibroblast activation and ameliorates tissue fibrosis by inhibition of mitochondrial translation
Location: Hall F1
Abstract Poster Presenter: Xuezhi Hong, MD – Department of Rheumatology, University Hospital Dusseldorf, Medical Faculty of Heinrich Heine University, Dusseldorf, Germany
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0976: LMPTP Drives Fibrosis in Systemic Sclerosis via TGF-beta Signaling Activation
0982: Impact of Immunosuppressive Therapies on Shingrix Vaccine Response in Immune-Mediated Inflammatory Diseases
Location: Hall F1
Abstract Poster Presenter: Cristiana Sieiro Santos, MD – Centre for Musculoskeletal Research, School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0983: Detecting Autoreactive CD4+ T Cells Relevant to Mixed Connective Tissue Disease
0987: S-4321, a novel dual-cell bifunctional PD-1:FcγRIIb selective agonist antibody for autoimmune disease, maintains expression of PD-1 on target cells and enhances inhibitory receptor expression on T cells in vivo
0990: An Fc-engineered Agonistic anti-pd-1 Antibody Selectively Depletes pd-1+ Cells and Attenuates T Cell Activation in vitro and in vivo in a Xenogeneic Graft-versus-host Disease (GvHD) Model
0991: MTHFD2 is a Novel Metabolic Target in Autoimmune Disease
Location: Hall F1
Abstract Poster Presenter: Laura McMillan – Sitryx Therapeutics
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0992: FoxP3Lo CD4+ T cells are functionally suppressive and expanded in the immune-mediated fibrotic diseases IgG4-related disease and systemic sclerosis
0993: NOD2 mutations mediate IL-17 predisposition in patients with Blau syndrome
Location: Hall F1
Abstract Poster Presenter: Leah Huey, BS – Oregon Health & Science University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0994: UTAA91: An Off-the-Shelf Allogeneic CAR-Vδ1T Therapy Leveraging CD19 Nanoantibody for B-cell Depletion and PD-1 Agonist Nanoantibody for Pathogenic T-cell Elimination in Refractory Autoimmune Diseases
Location: Hall F1
Abstract Poster Presenter: Lin Yang, PhD – PersonGen BioTherapeutics(Suzhou) Co., Ltd., Suzhou, China; PersonGenAnke Cellular Therapeutics Co., Ltd.,Hefei, China; Cyrus Tang Medical Institute, Soochow University, Suzhou, Jiangsu, China
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0995: Resident Memory T Cells Stimulate Pathogenic Activity in Fibroblast-like Synoviocytes
Location: Hall F1
Abstract Poster Presenter: Madison Mangin, BS – Boston Children's Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0996: Breaking Inflammatory Pathways: ELN28, a Novel Dual TNFα/JAK Inhibitor Drug Conjugate for Chronic Inflammation
1000: A Deep-learning Based Approach Uncovers Novel Mediators of Micro-rna Restraint of type-2 Immunity
Location: Hall F1
Abstract Poster Presenter: Shaan Sekhon, BA – CNU College of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1001: LBL-057, a Novel ADCC Enhanced PD-1 Agonist VHH-Fc Antibody
Location: Hall F1
Abstract Poster Presenter: Xiao Huang, MS – Leads Biolabs
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1002: ATF3 Inhibits Pulmonary Fibrosis via CD4+CD25−LAG3+ T Cells
Location: Hall F1
Abstract Poster Presenter: Xiao Zhang, n/a – The Eighth Affiliated Hospital of Sun Yat-sen University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1003: Potent Engineering of Polyfunctional CD8+ T Cells by a Novel In Vivo CAR mRNA Product Candidate (CPTX2309) in a Targeted Lipid Nanoparticle (tLNP) Utilizing CellSeekerTM Technology
Location: Hall F1
Abstract Poster Presenter: Yan Zhang, PhD – Capstan Therapeutics
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1004: Single-Cell Analysis Reveals Tissue Resident Memory T Cells Heterogeneity in the Joint
Location: Hall F1
Abstract Poster Presenter: Yang Yang, PhD – Boston Children's Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1005: CD49a Contributes to Binding and Survival of Synovial Resident Memory T cells
1008: Nationwide Historical Cohort Study on the Primary Prophylactic Effects of Colchicine in Cardiovascular Events
Location: Hall F1
Abstract Poster Presenter: Ahmet Gül, MD – Istanbul University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1009: Pregnancy Outcomes and Comorbidities Among Individuals with Systemic Lupus Erythematosus: A Nationwide Study Using Publicly Funded Health Insurance Claims Data
1010: Confounding by Indication in Observational Studies Investigating Glucocorticoid-Associated Adverse Events in Patients with Rheumatoid Arthritis: A Systematic Literature Review
1011: Model-based Evaluation of the Potential Public Health Impact of Expanding Medicare Coverage for Weight Loss Medications for Beneficiaries with Knee Osteoarthritis and Obesity in the US.
Location: Hall F1
Abstract Poster Presenter: Ethan Eickmann, BA – Brigham and Women's Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1012: Racial and Gender Disparities in Gout Clinical Trials
1017: Effectiveness of Recombinant Zoster Vaccine in Reducing Herpes Zoster Incidence and All-Cause Mortality Among Rheumatoid Arthritis Patients: A Retrospective Cohort Study of 21,046 Individuals from TriNetX U.S. Collaborative Network
1018: Factors Associated with Mortality in Systemic Lupus Erythematosus under a Universal Healthcare System: Results from the CAPTURED Study, a Population-Based Cohort in Catalonia, Spain
1019: Associations Between Mental Health Diagnoses and Acute Care Use Among Individuals with Systemic Lupus Erythematosus in the All of Us Research Program
Location: Hall F1
Abstract Poster Presenter: Karen Costenbader, MD, MPH – Brigham and Women's Hospital/ Harvard Medical School
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1020: Cohort Study of European Ancestry, Geographic Region, Ambient Ultraviolet Irradiance and the Risk of Developing Polymyalgia Rheumatica among Women
Location: Hall F1
Abstract Poster Presenter: Karen Costenbader, MD, MPH – Brigham and Women's Hospital/ Harvard Medical School
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1021: Recent Trends in Cannabis Use Among Individuals with Rheumatic Diseases
1027: GLP-1 Receptor Agonists to Facilitate Weight Loss and Improve Disease Activity, Pain and Function in Patients With Rheumatic and Musculoskeletal Disease: Real-World Evidence From the Rheumatology Informatics System for Effectiveness (RISE) Registry
1028: Enhanced Assessment of Psoriatic Arthritis Disease Progression Using cDAPSA plus the Contrast of Patient Reported Pain and Global Assessment versus Joint Counts
1031: Trends and Gender Disparities in Rheumatoid Arthritis Burden in the United States: A Population-Based Time-Trend Analysis Using the Global Burden of Disease Database, 1990–2021
Location: Hall F1
Abstract Poster Presenter: Satani Sharkas, MD – Boston Medical Center - Brighton
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1032: Exploring the role of the gut microbiome in gout: Prospective analysis of dietary fiber intake and the risk of gout
Location: Hall F1
Abstract Poster Presenter: Sharan Rai, PhD – Massachusetts General Hospital, Harvard Medical School
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1033: Rethinking ANA in Rheumatoid Arthritis: ICAP Pattern Insights from a Large-Scale Taiwanese Cohort
1035: Demographic and Clinical Correlates of 30 day Re-admission or Death During Admission in Patients With Rheumatologic Conditions : A Retrospective Cohort Analysis in a Single Academic Center
1037: Risk Factor Identification and Dynamic Individualized Prediction of Muscle Involvement in Systemic Sclerosis
Location: Hall F1
Abstract Poster Presenter: Zixing Liu, MS – Johns Hopkins University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1057: Leveraging Social Risk Factor Screening Infrastructure in Rheumatology Clinics to Respond to Rising Rates of Tuberculosis Among Individuals Experiencing Homelessness
1083: How Do Social Determinants of Health Differ Across Age and Disability Groups Among Adult Medicare Advantage Enrollees with Systemic Lupus Erythematosus?
1088: Unsupervised characterization of immune checkpoint inhibitor induced inflammatory arthritis using cluster and latent class analysis: result from a multicenter prospective registry
Location: Hall F1
Abstract Poster Presenter: Alice Tison, n/a – LBAI, UMR1227, University of Brest, CHU Brest, Brest, France
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1089: Comparing the immunosuppressant burden in immune checkpoint inhibitor mediated inflammatory arthritis versus polymyalgia rheumatica: results from a prospective multicenter registry
Location: Hall F1
Abstract Poster Presenter: Alice Tison, n/a – LBAI, UMR1227, University of Brest, CHU Brest, Brest, France
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1090: Quantitative Immunoglobulin Screening Prior to Rituximab Initiation: A Retrospective Cohort Study
1092: Prior history of arthritis and PD-1 over PD-L1 blockade predispose to immune-related adverse events in cancer patients treated with immune checkpoint inhibitors
Location: Hall F1
Abstract Poster Presenter: Binod Kc, MBBS – SUNY Upstate Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1093: Rituximab Associated Risk for Progressive Multifocal Leukoencephalopathy Among Patients with Systemic Lupus Erythematosus: A Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Blake Baay, BS – UT Southwestern
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1094: Changes in NK cells and TH cell phenotype in Rheumatoid Arthritis patients treated with janus kinase inhibitors: implications for adverse effects
Location: Hall F1
Abstract Poster Presenter: Carmen Lasa Teja, n/a – Division of Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Immunopathology Group, Santander, Spain.
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1095: Tolerance of non-TNF α treatments in patient with an inflammatory rheumatic (IRD) and autoimmune demyelinating diseases: French retrospective cases series
1096: Impact of IL-6 Receptor and JAK Inhibitors on Humoral Immunity in Inflammatory Rheumatic Diseases: An Ambispective Study.
Location: Hall F1
Abstract Poster Presenter: Elisabet Perea-Martínez, MD – Rheumatology section, Hospital General Universitario de Elda
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1097: Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic review and meta-analysis highlighting differences with the idiopathic forms
Location: Hall F1
Abstract Poster Presenter: Elvis Hysa, MD – University of Genova
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1098: Tolerability of Apremilast: Gastrointestinal Side Effects Dominate While Cardiac Safety Remains Reassuring
Location: Hall F1
Abstract Poster Presenter: Francisco Arias, MD – University of Texas Rio Grande Valley
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1099: Safety and Effectiveness of Hydroxychloroquine in the Treatment of Rheumatic Immune-Related Adverse Events
Location: Hall F1
Abstract Poster Presenter: Grace Haeun Lee, BA – Massachusetts General Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1100: Associations Between Pre-existing Autoimmunity and CAR T Cell Therapy Toxicity for Cancer Treatment: A Nationwide Retrospective Cohort Study
1101: Distinct Clinical Phenotypes of Immune Checkpoint Inhibitor–Associated Arthritis: Comparative Analysis of Inflammatory Arthritis, Polymyalgia Rheumatica-like, Activated Crystalline, and Activated Osteoarthritis
Location: Hall F1
Abstract Poster Presenter: Heba Altarawneh, MD – Massachusetts General Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1102: Checkpoint Inhibitor Inflammatory Arthritis: Single Center Case Identification and Chart Validation.
Location: Hall F1
Abstract Poster Presenter: Julia Barasch, MD – Weill Cornell - New York Presbyterian
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1103: Validation of the Health Assessment Questionnaire Disability Index in Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis
Location: Hall F1
Abstract Poster Presenter: Kayla Chubbs, MD – Dalhousie University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1104: Immune Checkpoint Inhibitors and Cardiovascular Risk in Patients with Rheumatoid Arthritis and Cancer
Location: Hall F1
Abstract Poster Presenter: KEVIN SHENG- KAI MA, DDS – Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1105: Association Between Pre-existing Rheumatoid Arthritis and Immune-related Adverse Events in Patients with Cancer Receiving Immune Checkpoint Inhibitors
Location: Hall F1
Abstract Poster Presenter: KEVIN SHENG- KAI MA, DDS – Center for Global Health, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania, United States
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1106: Faster Ellipsoid Zone Loss in Hydroxychloroquine Retinopathy with Tapering versus Discontinuation: A Longitudinal Optical Coherence Tomography Study from a Single Center in Taiwan
Location: Hall F1
Abstract Poster Presenter: KO JEN LEE, MD, PhD – National Taiwan University Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1107: Baseline Data on Rheumatic Immune-related Adverse Events from the Largest Prospective Multicenter US Consortium
Location: Hall F1
Abstract Poster Presenter: Laura Cappelli, MD – Johns Hopkins School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1108: Baseline Features, Immunosuppression, and Immune-related Adverse Events in Patients with Pre-existing Rheumatic Disease and Cancer Requiring Immune Checkpoint Inhibitor Therapy
Location: Hall F1
Abstract Poster Presenter: Laura Cappelli, MD – Johns Hopkins School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1109: Characteristics of SARS-CoV-2 infected Patients with Rheumatic Diseases on Rituximab: A Subanalysis of the COVID-19 Vaccine Booster in Immunocompromised Rheumatic Diseases (COVBIRD) Study
1113: Immune checkpoint inhibitor–associated myocarditis: Incidence, risk factors, and clinical outcomes in a global real-world cohort
Location: Hall F1
Abstract Poster Presenter: Qi Wang, MD – Metrohealth System/Case Western Reserve University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1114: Multi-omics Integration Analysis of the Cross-scale Mechanism of MTX-induced T2DM Risk and the Precise Intervention Strategy of Leonurine
Location: Hall F1
Abstract Poster Presenter: Qiang Xu, n/a – Guangzhou University of Traditional Chinese Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1115: Evaluation Of The Global Toxicity Burden In Patients Treated With Checkpoint Inhibitors Addressed For a Rheumatologic Toxicity And Its Impact On Oncological Outcomes
Location: Hall F1
Abstract Poster Presenter: Samuel Bitoun, MD, PhD – Université Paris-Saclay, Hôpital Bicêtre, Assistance Publique-Hôpitaux de Paris, FHU CARE, Inserm UMR 1184
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1116: Second-line Therapy for Immune-checkpoint Inhibitor-induced Pneumonitis
1118: Increased Risk of Azathioprine-Induced Leukopenia in Patients with Systemic Lupus Erythematosus: A 10-Year Retrospective Cohort Study at a Quaternary Care Hospital in Thailand
1120: Synergistic Effects of IL-17F and IL-17A on Neutrophil Chemotaxis: Increased Risk of Candidiasis with Dual Blockade of IL-17A and IL17-F
Location: Hall F1
Abstract Poster Presenter: Siba Raychaudhuri, MD – UC Davis, School of Medicine/ VA Medical Center, Sacramento
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1121: Latent Class Analysis Identifies Distinct Phenotypes of Multisystem Immune-Related Adverse Events Predictive of Survival After Immune Checkpoint Inhibitors
Location: Hall F1
Abstract Poster Presenter: Tao Ming Sim, MBBS – National University Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1122: A Retrospective Study of Adverse Cardiovascular Events in Patients Started on JAK Inhibitors at Two Major Health Systems in Northeast Ohio: Analysis of the 2019 JAK Inhibitors FDA Boxed Warning for Increased Risk of Serious Heart-related Problems
1149: Patient Symptom State Demonstrates Validity for the Assessment of Disease Activity and Patient-reported Outcomes in Adults with SAPHO and Chronic Nonbacterial Osteomyelitis – A Longitudinal Response Profile Analysis in The SAPHO-CNO Study
1153: New Disease Classification in the Block? A 5-year Retrospective Review on Clinical Profiles and Mortality Outcomes of Patients Presenting with Hematoinflammatory Syndromes at a University Center in Florida
1154: Assessment of Damage Using the igg4-related Disease Damage Index
Location: Hall F1
Abstract Poster Presenter: Eduardo Martin-Nares, MD, MSc – Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1155: Zasocitinib (TAK-279), an Investigational, Oral, Allosteric, Selective TYK2 Inhibitor, in Moderate-to-Severe Plaque Psoriasis: Efficacy Analysis by Baseline Characteristics from a Randomized Phase 2b Trial
1157: Safety and Tolerability of a Recombinant Zoster Vaccine in Patients with Inflammatory Rheumatic Musculoskeletal Diseases: A Prospective Longitudinal Study over 12 Months
Location: Hall F1
Abstract Poster Presenter: Ella Steiner, -None- – Ruhr-University Bochum, Germany
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1158: Clinical and Genetic Features of CTLA-4 Haploinsufficiency : A Prospective Study in China
Location: Hall F1
Abstract Poster Presenter: guishan liu, PA – Peking Union Medical College Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1159: IL-18 Correlates with Pouchot Score and Inflammatory Biomarkers in Adult-Onset Still’s Disease: Insights From a Repeated Measures Study
Abstract Poster Presenter: Javier Narvaez, PhD – Hospital Universitario de Bellvitge
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1163: Clinical and Biomarker Characteristics of Inebilizumab-Treated Participants Who Experienced an IgG4-RD Flare During the Phase 3 MITIGATE Trial
Location: Hall F1
Abstract Poster Presenter: John Stone, MD, MPH – Massachusetts General Hospital , Harvard Medical School
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1164: Effect of TNF Inhibitors on the Postprandial Glucose Homeostasis Molecules: Amylin, Gastric Inhibitory Polypeptide, and Pancreatic Polypeptide in Rheumatic Patients
1165: Real-World On-Label Treatment Persistence Through 24 Months in Biologic-Naïve and Biologic-Experienced Patients with Psoriatic Arthritis: Comparison of Guselkumab versus Subcutaneous Tumor Necrosis Factor Inhibitors
1167: Clinical Characteristics and Outcomes of igg4-related Disease Patients Who Chose Watchful Observation Without Treatment Intervention: A Single-center Study
Location: Hall F1
Abstract Poster Presenter: Kanako Chujo, MD – Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1168: Interstitial Lung Disease-Associated Antibody Testing and Positivity Rates in Systemic Autoimmune Rheumatic Diseases from a National Reference Laboratory
1175: Secukinumab In Patients with Giant Cell Arteritis with Polymyalgia Rheumatica Symptoms: A Post Hoc Analysis of the Phase 2 TitAIN Study
Location: Hall F1
Abstract Poster Presenter: Nils Venhoff, MD – Department of Rheumatology and Clinical Immunology, Medical Center, Faculty of Medicine, University of Freiburg
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1176: VISIBLE Post-Inflammatory Pigmentation Journeys: Exploring the Impact of Pigmentation
1186: Increased Adoption of IL-1 Pathway Inhibition and the Steroid-sparing Paradigm Shift: Temporal Trends in Recurrent Pericarditis Treatment From the RESONANCE Patient Registry
1187: Myositis-Specific Antibody Profiles and Factors Associated With Rapidly Progressive Interstitial Lung Disease and Mortality in Antisynthetase Syndrome: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Tulaton Sodsri, MD – Texas Tech University Health Sciences Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1188: Aortic Wall Shear Stress May Be a Protective Factor Against Development of Spinal Osteoproliferation
Location: Hall F1
Abstract Poster Presenter: Umut Kalyoncu, n/a – Division of Rheumatology, Department of Internal Medicine, Hacettepe University School of Medicine, Ankara, Turkey
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1189: Clinical Outcomes and Response to SARS-Cov-2 Infection and Vaccination in Ianalumab‑Treated Patients with Autoimmune Diseases
1192: Idiopathic Inflammatory Myopathies: A Prospective Phase 4 Controlled Trial Of Recombinant Herpes Zoster Vaccine
Location: Hall F1
Abstract Poster Presenter: ANA PAULA LUPPINO-ASSAD, MD, PhD – Hospital das Clinicas da Faculdade de Medicina da Universidade de São Paulo (HC/FMUSP)
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1193: Lung Transplant Outcomes in Patients with Myositis- and Systemic Sclerosis-Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis
Location: Hall F1
Abstract Poster Presenter: Angela Chang, MD – University of British Columbia
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1194: Risk of Calcinosis with Proton Pump Inhibitor Use in Adult Dermatomyositis and Systemic Sclerosis
1198: Induction of stable, GC-free remission in patients with severe, therapy-refractory anti-synthetase syndrome after using the bispecific CD19xCD3 T cell engager blinatumomab
1201: Prognostic Significance of 1-Year Pulmonary Function Changes in Myositis-Associated Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Irada Choudhuri, MD – University of Pittsburgh Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1202: High Prevalence of Asymptomatic Interstitial Lung Disease in Idiopathic Inflammatory Myopathies: Validation of ACR/CHEST Risk Factors in a Hong Kong Cohort
Location: Hall F1
Abstract Poster Presenter: Iris Tang, MBBS, MRCP – Department of Medicine, LKS Faculty of Medicine, University of Hong Kong
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1203: Rituximab in Treatment Refractory vs Treatment Naive Anti Signal Recognition Particle (SRP) Myositis A Case Series
1205: Real-time MRI for assessment of swallowing impairment in inclusion body myositis and oculopharyngeal muscular dystrophy.
Location: Hall F1
Abstract Poster Presenter: Jens Schmidt, MD – Immanuel University Hospital Rüdersdorf, Brandenburg Medical School; Department of Neurology and Pain Therapy
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1206: Overexpression of lymphotoxin in autophagy-deficient mice as model for inclusion body myositis
Location: Hall F1
Abstract Poster Presenter: Jens Schmidt, MD – Immanuel University Hospital Rüdersdorf, Brandenburg Medical School; Department of Neurology and Pain Therapy
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1207: Cutaneous and Muscular Disease Trajectories in Adult Patients with Dermatomyositis
Location: Hall F1
Abstract Poster Presenter: Jesus Valencia, MD – Johns Hopkins Bayview Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1208: Neutrophil Activation in Juvenile Dermatomyositis: Associations with Muscle Function and Disease Progression
Location: Hall F1
Abstract Poster Presenter: Jia Shi, MD – University of Washington
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1209: Beyond Muscle Strength: Functional Performance Measures Enhance Assessment of Disease Activity in Juvenile Dermatomyositis
Location: Hall F1
Abstract Poster Presenter: Jia Shi, MD – University of Washington
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1210: Artificial Intelligence-based Capillaroscopy and Laboratory Biomarkers to Predict Disease Activity in Idiopathic Inflammatory Myopathies: Preliminary Data from the Capiami Cohort
1211: Plasma Levels of miR-133a-3p and miR-1-3p as Potential Biomarkers of Muscle Involvement and Initial Treatment Response in Myositis
Location: Hall F1
Abstract Poster Presenter: Kristina Svobodová, MD (she/her/hers) – Institute of Rheumatology and Department of Rheumatology, 1st Faculty of Medicine, Charles University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1212: Relapse in Idiopathic Inflammatory Myopathies: insights from extended MyoCite and Italian Consortia
Location: Hall F1
Abstract Poster Presenter: Maria Rosa Pellico, MD – ASST Pini-CTO, Clinical Rheumatology Unit
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1213: Transitional Changes on High Resolution Computed Tomography (HRCT) in idiopathic inflammatory Myopathy- Associated Interstitial Lung Disease (IIM-ILD)
1252: Can LLMs Categorize Patient Priorities Like Humans? Comparing AI and Human Coders in Arthritis Nominal Group Discussions
Location: Hall F1
Abstract Poster Presenter: Melissa Mannion, MD – University of Alabama at Birmingham
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1253: Patient Reported Outcome Measures: Assessing Resident Physician Acceptance of the Routine Assessment of Patient Index Data 3 Survey and its Impact on Physician-Patient Relationship
Location: Hall F1
Abstract Poster Presenter: Nisha Sapkota, MD – One Brooklyn Health- Interfaith Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1254: Symptom Burden and Treatment Experience in Fibromyalgia: Results From a National Patient Survey
1256: Quantitative Analysis of a Pilot Study: Integrating Behavioral Health Services for Patients with Rheumatic Diseases
Location: Hall F1
Abstract Poster Presenter: Shannon Teaw, MD – University of Washington
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1257: Integrated Behavioral Health Services for Patients with Rheumatic Diseases: Qualitative Analysis of a Pilot Study
Location: Hall F1
Abstract Poster Presenter: Shannon Teaw, MD – University of Washington
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1258: Upadacitinib in the treatment of Rheumatoid Arthritis - Interstitial Lung Disease. National multicenter study of 25 patients in clinical practice.
Location: Hall F1
Abstract Poster Presenter: Ana Serrano-Combarro, MD – Division of Rheumatology, Hospital Universitario Marques de Valdecilla, IDIVAL, Inmunopathology group, Santander
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1259: Patient and Caregiver Perspectives on the Burden of Disease in Uncontrolled Gout: A Cross-Sectional Survey Study
1264: Breaking the Veil: Preliminary Findings for a Qualitative Analysis of Rheumatoid Arthritis Patient Perspectives on Physical Activity and Mental Healt
1266: Shared Decision Making in Rheumatoid Arthritis: Is RA disease activity associated with patient reported measures of shared decision making pre-SDM intervention?
1267: Patient Reported Outcomes Predict Subsequent Treatment Intensification Among Rheumatoid Arthritis Patients: Longitudinal PRO Measurement Using a Mobile Health App
Location: Hall F1
Abstract Poster Presenter: Leah Santacroce, MS – Brigham and Women's Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1268: Development of the LupusCoach Chatbot: Results of a Focus Group
1277: Combination Therapy with Rituximab and Cyclophosphamide for Treating Pediatric Patients with Severe Manifestations of Rheumatic Disease
Location: Hall F1
Abstract Poster Presenter: Eileen Rife, MD – University of Alabama at Birmingham
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1278: Differences in Patient and Provider Perception of Functional Status in Adolescents with Lupus
Location: Hall F1
Abstract Poster Presenter: Emily Masi, MD, PhD – Cohen Children's Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1279: Whole Blood Gene Expression Defined Subgroups of Treatment Naïve Children and Adolescents with Childhood-onset Systemic Lupus Erythematosus.
Location: Hall F1
Abstract Poster Presenter: Reagan Reid, MSc – University of Toronto
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1280: Investigating the Association Between SARS-CoV-2 Infection, COVID-19 Vaccination, and Autoimmune Diseases in a Pediatric Population: A comprehensive analysis
1287: A Clear Pattern of Clinical Presentation in Juvenile Systemic Scleroderma Is Associated with Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Ivan Foeldvari, MD – Hamburger Zentrum für Kinder- und Jugendrheumatologie
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1288: Is gastroesophageal reflux a risk for interstitial lung disease in Juvenile systemic sclerosis?
Location: Hall F1
Abstract Poster Presenter: Ivan Foeldvari, MD – Hamburger Zentrum für Kinder- und Jugendrheumatologie
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1289: Longitudinal Exploration of Pain and Disease Characteristics in Youth with Childhood-Onset Lupus
Location: Hall F1
Abstract Poster Presenter: Jida Jaffan, MA – The Hospital for Sick Children/ University of Toronto
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1290: Adverse Childhood Experiences: Prevalence and Relationship to Disease and Mental Health Outcomes in Childhood-onset Systemic Lupus Erythematosus (cSLE)
1295: Neuropsychiatric Lupus in Children and Adolescents: Understanding Current Practices and Barriers to Care Perceived by Pediatric Rheumatology Clinicians in North America
Location: Hall F1
Abstract Poster Presenter: Martha Rodriguez, MD – Riley Hospital for Children at Indiana University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1296: Liver Biopsy Findings in Pediatric SLE: A Large Tertiary Center Experience
1298: Identifying Psychosocial Profiles in Youth with Chronic Musculoskeletal Pain: A K-Means Clustering Analysis of Resilience Subgroups
Location: Hall F1
Abstract Poster Presenter: Nellie Butler, BA – Children's Hospital of Philadelphia
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1299: Pediatric Antiphospholipid Syndrome in a Large Tertiary Center
Location: Hall F1
Abstract Poster Presenter: Rasha Elrefai, MD – Baylor College of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1300: International Assessment of cSLE Clinical Remission (cCR) Criteria in Childhood Lupus: Sensitivity Analyses from the UK JSLE Cohort and the CARRA Registry
1303: Impact of Fruits and Vegetables Intake on Immune-mediated Inflammatory Diseases：a Two-sample Mendelian Randomization Study
Location: Hall F1
Abstract Poster Presenter: Xuemei Tang, MD, Professor, Chief Physician – Department of Rheumatology and Immunology, Children's Hospital of Chongqing Medical University, National Clinical Research Center for Child Health and Disorders
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1304: The role of PET/CT in evaluating rheumatologic conditions in children with fever of unknown origin - a multicenter study
Location: Hall F1
Abstract Poster Presenter: YOEL Levinsky, MD – Schneider Children's Medical Cnetr of Israel, Tel Aviv University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1305: Clinical outcomes of low-to-moderate–dose glucocorticoids in multisystem inflammatory syndrome in children (MIS-C) - a multicenter study
Location: Hall F1
Abstract Poster Presenter: YOEL Levinsky, MD – Schneider Children's Medical Cnetr of Israel, Tel Aviv University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1306: Systematic Literature Review of Digital Sleep Outcomes and Endpoints Used to Assess Rheumatoid Arthritis
1320: Trends In Incidence and Risk factors For Incident Venous Thromboembolism in Patients with Rheumatoid Arthritis: A Population-Based Retrospective Cohort Study
1323: Efficacy of Olokizumab in Treating Comorbid Depression in Patients with Rheumatoid Arthritis: Results of a Single-Center Randomized Controlled Trial
1331: anti-beta-2-glycoprotein-1 Iga Antibodies Facilitate Macrophage Cholesterol Loading and Influence Coronary Atherosclerosis Progression in a Dose-dependent Manner in Rheumatoid Arthritis
1341: Physical Function Across Age in Patients With Rheumatoid Arthritis and Population Controls: A Cross-Sectional Study of Four Performance Measures
Location: Hall F1
Abstract Poster Presenter: Saskia Truijen, MSc – Maastricht University Medical Centre+
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1343: Six-Minute Walk Distance as a Functional Measure in Rheumatoid Arthritis-associated Interstitial Lung Disease Reflecting Both Lung and Joint Involvement
1346: Preliminary Result of Investigating the Response of Conventional Disease-Modifying Antirheumatic Drugs (cDMARDs) Associated SNPs: One Cohort Study
Location: Hall F1
Abstract Poster Presenter: YU Chen, MD, MSc, BA (she/her/hers) – 1. Division of Rheumatology, Allergy and Immunology, Far Eastern Memorial Hospital, New Taipei City, Taiwan, R.O.C.
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1347: The Better Disease-modifying antirheumatic drug (DMARD)? Efficacy and Safety of Methotrexate Versus Leflunomide Monotherapy in Rheumatoid Arthritis: A Systematic Review and Meta-Analysis
1348: Real World Evaluation on the Effectiveness of Baricitinib or Other Treatments in Patients With Rheumatoid Arthritis: Data from the European and Non-European Cohorts of the RA-BE-REAL Study
Location: Hall F1
Abstract Poster Presenter: AJ Fernandez, n/a – Eli Lilly and Company
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1349: Achievement of Treatment Targets and Maintenance of Response with Upadacitinib in Patients with Moderate-to-severe Rheumatoid Arthritis in a Real-world Setting: Final 2-year Outcomes from the UPHOLD Study
Location: Hall F1
Abstract Poster Presenter: Andrew Ostor, MD – Australian National University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1350: Initial Biologic Therapy Improves Sexual Function in Female Patients with Rheumatoid Arthritis: A 6 Month Follow-Up Study
Location: Hall F1
Abstract Poster Presenter: Daniel Zavada, MD – Charles University, Third Faculty of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1351: Are Glucocorticoids Associated with Worse Overall Survival Among Rheumatoid Arthritis Patients Treated with Immune Checkpoint Inhibitors? The Confounding Effect of Dexamethasone
1353: Phase 3 Study of the Efficacy, Safety and Immunogenicity of the Proposed Tocilizumab Biosimilar RGB-19, Intravenously Administered to Participants With Active Rheumatoid Arthritis: 52-Week Data
1354: Effect of Ivarmacitinib on Joint Swelling and Tenderness in Patients with Moderate-to-severe Rheumatoid Arthritis: A Post-hoc Study of a Phase III Clinical Trial
Location: Hall F1
Abstract Poster Presenter: Hongtao Jin, MD – The Second Hospital of Hebei Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1355: Use of parenteral compared to oral glucocorticoids in early rheumatoid arthritis is superior for chance ofbeing off steroids and escalation of therapy at 1 year
1359: Comparative Safety Outcomes of Tofacitinib Versus Upadacitinib in Patients with Rheumatoid Arthritis: A Retrospective Cohort Study
Location: Hall F1
Abstract Poster Presenter: Maya Khasho, MD – University of central florida
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1360: Evaluating Causal Effects of Biologic and Targeted Synthetic Disease-modifying Anti-rheumatic Drugs Targets in Rheumatoid Arthritis Using Mendelian Randomisation
1361: Efficacy of Telitacicept in the treatment of Connective tissue disease-associated interstitial lung disease: A Potential therapeutic option
Location: Hall F1
Abstract Poster Presenter: Mingfang Sun, MD – Department of Rheumatology & Clinical Immunology, Daping Hospital & Research Institute of Surgery, Army Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1362: Multimodal Spatial and Single-Cell Profiling of Synovial Tissue Reveals Macrophage Programs Associated with Biologic TherapyTreatment Response in Rheumatoid Arthritis
1363: Evaluation of the Clinical Outcome of Baricitinib in Patients with Rheumatoid Arthritis from Multi-center Collaborative Study in Japan: Sub-analysis for Difficult-to-treat RA.
Location: Hall F1
Abstract Poster Presenter: NAOKI Kondo, MD, PhD – Division of Orthopedic Surgery, Niigata University Medical and Dental General Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1364: Efficacy Of Ayurvedic Treatment Versus Placebo, Each In Combination With Methotrexate In Early RA Over 20 Weeks: An Exploratory Randomized Control Trial
1365: Economic impact of early treatment and strict disease control in rheumatoid arthritis: a cost-minimization approach concerning biological therapy
1366: Cost Per Responder Analysis of Certolizumab Pegol Versus Adalimumab in Patients with Moderate to Severe Active Rheumatoid Arthritis and High Rheumatoid Factor Levels: A Payer Perspective from Canada and Brazil
1371: Effect of bDMARDs and tsDMARDS on diffuse interstitial lung disease associated with rheumatoid arthritis: systematic review and meta-analysis
Location: Hall F1
Abstract Poster Presenter: Stéphane HILLIQUIN, n/a – Département de Rhumatologie, Hôpital Cochin, Assistance publique des Hôpitaux de Paris, Université Paris-Cité, Paris, France
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1372: Treatment Patterns and Outcomes After Janus Kinase Inhibitor Discontinuation in Rheumatoid Arthritis: A Real-World Cohort Study
Location: Hall F1
Abstract Poster Presenter: Sungwon Ko, MD – ASAN MEDICAL CENTER
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1373: Effect of JAK Inhibitors on Bone Mineral Density in Rheumatoid Arthritis Patients with Osteoporosis: A Comparative Study with Biologics
Location: Hall F1
Abstract Poster Presenter: Sungwon Ko, MD – ASAN MEDICAL CENTER
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1374: AZD1163, a Novel Bispecific Human Antibody Targeting PAD2/4 Enzymes Responsible for Generating Citrullinated Protein Auto-antigens in Rheumatoid Arthritis, Demonstrates Dose-dependent Inhibition of Systemic PAD Activity in Healthy Volunteers
1375: 86-96% of Rheumatoid Arthritis (RA) Patients with RA Who Have 0 or 1 Swollen Joint or Tender Joint but Are Classified as Moderate/high on RA Indices Have 1-9 Comorbidities Recognized on a Multidimensional Health Assessment Questionnaire (MDHAQ)
1391: Assessment of Anti-ssa/ro Testing Across Various Commercial Laboratories in the United States to Reduce the Burden of Surveillance in Pregnant Women with No History of Fetal Atrioventricular Block (fAVB)
Location: Hall F1
Abstract Poster Presenter: Mala Masson, BA – NYU Langone Medical Center- Division of Rheumatology
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1392: Cancer Mortality in Sjogren’s Disease: Disproportionate Increase in Mortality from Cancers in Sjogren’s Disease Relative to All-Cancers
1405: A Combined Score of Syndesmophytes and Facet Joint Ankylosis Improves Sensitivity to Spinal Structural Damage Progression in Axial Spondyloarthritis
1407: Trends in Diagnostic Timing and Clinical Features of Axial Spondyloarthritis by Sex and Clinical Subtype: A Multicenter Cohort Over Seven Decades
Location: Hall F1
Abstract Poster Presenter: Carla Saad, MD, PhD – Faculdade de Medicina da Universidade de Sao Paulo
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1408: When Damage and Disability Diverge: Unraveling Sex-Based Drivers of Axial Spondyloarthritis Burden
Location: Hall F1
Abstract Poster Presenter: Carla Saad, MD, PhD – Faculdade de Medicina da Universidade de Sao Paulo
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1409: The impact of depression in axial spondyloarthritis: Epidemiological insights from the Ankylosing Spondylitis Registry of Ireland (ASRI)
1410: Examining the Interchangeability of Two Different Patient-Reported Global Assessment Measures in an Observational Axial Spondyloarthritis Cohort
Location: Hall F1
Abstract Poster Presenter: Connor Vershel, MD – University of Texas at Houston
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1411: Defining Minimal Disease Activity (MDA) in Psoriatic Arthritis (PsA) with the inclusion of Psoriatic Arthritis Impact of Disease (PsAID) scores rather than Health Assessment Questionnaire (HAQ)
1414: Multidimensional Assessment to Differentiate Early Psoriatic Arthritis from Cutaneous Psoriasis
Location: Hall F1
Abstract Poster Presenter: Eugeniu Russu, MD, PhD – State Medical and Pharmaceutical University ”Nicolae Testemitanu”; "Timofei Mosneaga" Republican Clinical Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1415: The Association of Handedness with Radiographic Damage in Patients with Psoriatic Arthritis
Location: Hall F1
Abstract Poster Presenter: Fadi Kharouf, MD – Hadassah Medical Center - Toronto Western Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1417: Common Causes of Hospitalization in Spondyloarthritis Patients: A Nationwide Analysis
Location: Hall F1
Abstract Poster Presenter: Faria Sami, MD – The University of Alabama at Birmingham
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1418: Impact of Type 2 Diabetes Mellitus on Cardiovascular Outcomes in Patients with Ankylosing Spondylitis on NSAID Therapy
1419: Effectivenss of an educational program on non-radiographic axial spondyloarthritis
Location: Hall F1
Abstract Poster Presenter: Hideto Kameda – Toho University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1420: A Nationwide Analysis of In-Hospital Mortality in Adult Ankylosing Spondylitis
Location: Hall F1
Abstract Poster Presenter: Isadora Small, n/a – The Latin School of Chicago
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1421: Impact of Psoriatic Arthritis Disease Activity and Fatigue on Subjective Cognitive Decline (“Brainfog”)
Location: Hall F1
Abstract Poster Presenter: Lily Mikolajczak, BS – Georgetown University School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1422: Assessment of Difficulties, Modifications and Use of Work Adaptations in Patients with Axial Spondyloarthritis: Validation of the Dificultax and Modal Questionnaires
1434: Safety of Prescription NSAIDs in Adults with IBD: Data from a Large Administrative Claims Cohort
Location: Hall F1
Abstract Poster Presenter: Adam Mayer, MD – Hackensack University Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1435: Impact of Treatment With Upadacitinib on Non-Nociceptive Pain and Its Relevance for the Presence of Residual Symptoms in Axial Spondyloarthritis: Results from a Multicountry Observational Study
1436: Angiogenesis Markers in Difficult to Treat Psoriatic Arthritis Patients
Location: Hall F1
Abstract Poster Presenter: Devy Zisman, MD – Carmel Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1437: Characterization of ORKA-002, a Novel Extended Half-life Monoclonal Antibody Targeting IL-17A/F for the Treatment of Psoriasis and Other Indications
1438: Similar Efficacy of Bimekizumab in Two Clinical Endotypes of Axial Spondyloarthritis: 2-Year Results from Two Phase 3 Studies and Their Open-Label Extension
1441: Efficacy and Safety of Vunakizumab in Patients with Active Ankylosing Spondylitis by Cigarette Smoking Status: A Post Hoc Analysis of a Randomized, Double-blind, Phase 2/3 Study
Location: Hall F1
Abstract Poster Presenter: Hongbin Li, MD – Affiliated Hospital of Inner Mongolia Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1442: Modulation of Soluble Biomarkers of Cartilage and Bone Turnover and Inflammation by Zasocitinib (TAK-279), an Oral, Allosteric, Highly Selective and Potent TYK2 Inhibitor, is Associated with Clinical Response in Patients with Active Psoriatic Arthritis
1444: Real-world comparative effectiveness of tofacitinib, tumor necrosis factor inhibitors, and interleukin-17 inhibitors among patients with axial spondyloarthritis
1445: Patient Characteristics, and Physician-Reported Treatment Effectiveness and Treatment Satisfaction with Bimekizumab for Axial Spondyloarthritis in the United States: Interim Analysis from a Real-World Study
Location: Hall F1
Abstract Poster Presenter: Jessica Walsh, MD, MBA – Salt Lake City Veterans Affairs Health and University of Utah Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1446: Persistence of Second-line Treatment in Anti-TNF-experienced Axial Spondyloarthritis Patients: Comparing Cycling Anti–TNF vs Switching to a Different Mechanism of Action
1447: Long-term impact of secukinumab on the prevention of psoriatic arthritis in patients with psoriasis: a 5-year pooled analysis of the ERASURE, FIXTURE and SCULPTURE studies
1449: Bimekizumab Demonstrated Comparable One-Year Efficacy in Male and Female Patients with Axial Spondyloarthritis: Results from Two Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Lianne S. Gensler, MD – University of California San Francisco
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1450: The Novel Digital Therapeutic Axia Improves Disease Activity, Functionality, and Quality of Life in Axial Spondyloarthritis Patients: Results from a Randomized Controlled Trial (Bechterew-App Trial)
Location: Hall F1
Abstract Poster Presenter: Marc Schmalzing, MD – University Hospital Wuerzburg
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1451: Bimekizumab was Efficacious Regardless of Age, BMI, CRP, or HLA-B27 Status: 1-Year Results from Two Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Marina Magrey, MD – Case Western Reserve University School of Medicine/University Hospitals Cleveland
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1452: Clinical and Demographic Characteristics of Treatment-Refractory Axial Spondyloarthritis: Data from the Greek AxSpA Registry
1453: Real-World Comparative Effectiveness of Upadacitinib in Psoriatic Arthritis: Evaluation of Switching to Upadacitinib Versus Tumor Necrosis Factor Inhibitors or Interleukin-17 Inhibitors After First-Line Tumor Necrosis Factor Inhibitors
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1454: Long-Term Safety and Tolerability of Bimekizumab Treatment Across Phase 2b and Phase 3 Studies in Patients with Axial Spondyloarthritis or Psoriatic Arthritis: 3-Year Update from the Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1455: Sonelokimab in Patients With Active Psoriatic Arthritis Who Are Naive to Biologic DMARDs: Phase 2 ARGO Analysis and Phase 3 IZAR-1 Study Design
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1456: Long-Term Safety of Tildrakizumab Through Week 208 in Patients With Psoriatic Arthritis: Results From the Phase 2b Open-Label Extension Study
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1457: Real-world Patient Trajectories in Psoriasis and Psoriatic Arthritis: a Retrospective Study
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1458: Clinical Efficacy of Bimekizumab Treatment up to 2 Years Across Patients with Psoriatic Arthritis and Varying Baseline Joint Involvement: Results from a Post Hoc Analysis of Two Pooled Phase 3 Studies
Location: Hall F1
Abstract Poster Presenter: Philip Mease, MD – Swedish Medical Center/Providence St. Joseph Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1459: Fungal Infections, Including Candida, in Patients With Active Psoriatic Arthritis (PsA) Treated With Secukinumab: A Pooled Analysis of 9 Phase 3 Trials
1460: Effect of Guselkumab and IL-17 Inhibitors on Work Productivity and Activity Impairment in Psoriatic Arthritis: 6-Month Results of the PsABIOnd Observational Study
1461: Digital Behavioral Therapy Improves Outcome in Patients With Axial Spondyloarthritis And Persistent Pain: Results From a Randomized Controlled Trial
1462: Five-Year Results of Secukinumab on Minimal Disease Activity (MDA) Components and the Impact of Biologic Treatment Status on Effectiveness and Safety in Patients With Psoriatic Arthritis: Real-World Data From the SERENA Study
1464: Incidence of Major Adverse Cardiovascular Events (MACE) in Psoriasis, Psoriatic Arthritis and Axial Spondyloarthritis Patients With and Without Cardiovascular Risk Factors Treated With Secukinumab: Five-Year Safety Data from the Real-World SERENA Study
1465: Sustainability of Clinical Response Through 2 Years Among Upadacitinib-Treated Patients With Axial Spondyloarthritis: Data From the SELECT-AXIS 1 and SELECT-AXIS 2 Trials
1466: Impact of Bimekizumab on Spinal MRI Inflammation and Structural Lesions in Patients with Radiographic Axial Spondyloarthritis: 2-Year CANDEN Scoring Results from a Phase 3 Study and Its Open-Label Extension
1469: Remission, Low Level Disease Activity State (LLDAS) and Relapse in Patients With Early-Onset, Adult-Onset and Late-Onset Systemic Lupus Erythematosus
1477: Can Large Language Models Support Clinical Decision-Making in Atypical SLE? A Comparative Analysis
Location: Hall F1
Abstract Poster Presenter: Beste Acar, MD – Cerrahpasa Faculty of Medicine, Istanbul University-Cerrahpasa
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1478: Construction and Validation of a Prediction Model of Cognitive Dysfunction in Patients with Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Bin zhou, MD – The First School of Clinical Medicine, Southern Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1479: Validation of Attention, Memory, and Frontal-Executive Abilities Screening Test (AMFAST) in Systemic Lupus Erythematosus (SLE), a prospective single-center study in The Bronx
Location: Hall F1
Abstract Poster Presenter: Chen Chao, MD, MBA – Montefiore Medical Center/Albert Einstein College of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1480: Urinary Biomarkers Detect Proliferative Lupus Nephritis in SLE Patients with Subclinical Proteinuria.
Location: Hall F1
Abstract Poster Presenter: Chen-Yu Lee, MD – Johns Hopkins University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1481: Duffy Antigen Screening in Systemic Lupus Erythematosus Patients with Neutropenia: A Quality Improvement Initiative
1482: Evaluation of T Cell Subpopulations, CD4/CD8 Ratio and p16INK4a in Patients with Systemic Lupus Erythematosus and Cognitive Impairment
Location: Hall F1
Abstract Poster Presenter: Erik Cimé-Aké, n/a – Instituto Nacional de Ciencias Médicas y Nutrición. Salvador Zubirán. Immunology and Rheumatology Department
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1483: Evidence of Early Cardiovascular Dysfunction in Young Systemic Lupus Erythematosus Patients Compared to Older Healthy Controls
1486: Systemic Lupus Erythematosus and Statins in GLADEL 2.0: Are Cardiovascular Risk Prevention Guidelines Being Followed?
Location: Hall F1
Abstract Poster Presenter: Ileana Cecilia Reynosa Silva, MD – Universidad Autonoma de Nuevo Leon, Hospital Universitario "Dr. Jose Eleuterio Gonzalez"
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1487: Whole Health Empowerment for Endotypes of Lupus (WHEEL) Program: User Testing Findings on Feasibility, Acceptability, and Opportunities for Intervention Refinement
1493: Long-Term Outcomes in Systemic Lupus Erythematosus Patients Infected with SARS-CoV-2: Variant-Specific Analysis of Pre-Delta/Delta and Omicron Periods
1496: Demyelinating Syndromes in Systemic Lupus Erythematosus: A 23-Year Retrospective Analysis of Clinical Features and Treatment Outcomes from a Tertiary Care Center
Location: Hall F1
Abstract Poster Presenter: Manikandan Gopal, DM – Christian Medical College Vellore
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1497: Acute Care Utilization in Patients with Antiphospholipid Syndrome And/or Systemic Lupus Erythematosus
1500: Prognostic Impact of Thrombocytopenia on Morbidity and Mortality in Systemic Lupus Erythematosus: A Retrospective Single-Center Study
Location: Hall F1
Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1501: Thrombocytopenia in SLE: A Hidden Prognostic Marker of Increased Mortality and Adverse Outcomes - Results from Real World Data
Location: Hall F1
Abstract Poster Presenter: Milad Heydari-Kamjani, DO – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1502: Prevalence and Associated Factors of Autoimmune Hepatitis and Primary Sclerosing Cholangitis in Systemic Lupus Erythematosus: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Omer Pamuk, MD – University Hospitals Cleveland Medical Center/ Case Western Reserve University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1503: Lupus Disease Activity Adversely Affects the Quality of Life but not Intimate Relationship and Sexual Function in Indian Female Lupus Patients
1504: High prevalence of clonal hematopoiesis of indeterminate potential (CHIP) somatic mutations in a cohort of 1,073 SLE participants
Location: Hall F1
Abstract Poster Presenter: Richard Oppong, PhD – NATIONAL INSTITUTES OF HEALTH
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1505: Discordance Between Physician and Patient Global Assessment of Disease Activity in a Large Multicenter Prospective SLE Cohort in the U.S. and Canada
Location: Hall F1
Abstract Poster Presenter: Romy Kallas, MD, MS – Hospital for Special Surgery
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1506: Perspectives on Clinical Trial Participation for Novel Advanced Therapies: A Focus Group Study in Systemic Lupus Erythematosus (SLE)
Location: Hall F1
Abstract Poster Presenter: Sasha Bernatsky, MD,PhD – Research Institute of the McGill University Health Centre
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1507: Temporal Trends in the Incidence of Systemic Lupus Erythematosus (SLE) in the United States (US): Holding Steady?
Location: Hall F1
Abstract Poster Presenter: Sasha Bernatsky, MD,PhD – Research Institute of the McGill University Health Centre
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1508: Dissecting the Role of T Cell Subsets and Complements in Lupus Pathogenesis in Systemic Lupus Erythematosus Patients with Obesity
Location: Hall F1
Abstract Poster Presenter: Sheila Serin, MD – Ochsner Clinic Foundation
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1509: Outcome of Newly Diagnosed SLE with Serositis and Its Clinical Features in Daily Clinical Practice: A Single Center Study
1510: Biomarker landscape for neuropsychiatric involvement in patient with systemic lupus erythematosus
Location: Hall F1
Abstract Poster Presenter: Sitian Zang, n/a – Department of Rheumatology and Immunology, Peking University People’s Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1511: Mental Health and Medical Burden: The Impact of Depression on Length of Stay in Lupus Patients
Location: Hall F1
Abstract Poster Presenter: Sophia Chang Stauffer, MPH – Mount Sinai Hospital, Sinai Urban Health Institute and Univ.of Illinois @ Chicago, Dept Medicine, Div. Endocrinology
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1512: anti-u1-rnp Antibody Positivity Is Associated with Elevated Interferon Score in SLE Irrespective of Disease Activity: A Transcriptome Analysis in Japanese Patients
Location: Hall F1
Abstract Poster Presenter: Takemichi Matsui, MD – Icahn School of Medicine at Mount Sinai
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1513: Race, Renal Failure, and Risk: A five-to-ten year retrospective cohort study of Racial differences in outcomes of patients with dialysis-dependent Lupus nephritis
Location: Hall F1
Abstract Poster Presenter: Ufuoma Mamoh, MBChB – Medstar Georgetown University (Baltimore) Internal Medicine Residency
Abstract Poster Presenter: Yan Wang, n/a (she/her/hers) – Department of Rheumatology and Immunology, Peking University People's Hospital, Beijing, China
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1515: Machine Learning–defined Subtypes of Systemic Lupus Erythematosus Identify Distinct Immunologic and Molecular Signatures
Location: Hall F1
Abstract Poster Presenter: Yuke Hou, MD – Peking University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1517: The Chinese Experience with Telitacicept in Lupus Nephritis Management: 51-Patient Cohort Analysis on Therapeutic Outcomes and Safety Parameters
Location: Hall F1
Abstract Poster Presenter: Aijing Liu, PhD – Department of Rheumatology and Immunology, The Second Hospital of Hebei Medical University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1518: Efficacy and Safety of Anifrolumab in Discoid Lupus: A Meta-Analysis of the Literature
Location: Hall F1
Abstract Poster Presenter: Ali Ali, MD, RhMSUS – Department of Internal Medicine, Division of Rheumatology, Henry Ford Health System
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1519: Post-hoc Analysis of Sustained Response Over Time in Systemic Lupus Erythematosus Patients Treated with Cenerimod in CARE (Phase 2 B) Study
1520: Long-Term Effects of Obinutuzumab on Kidney Function in Lupus Nephritis
Location: Hall F1
Abstract Poster Presenter: Bahtiyar Toz, MD – Zucker School of Medicine at Hofstra/ Northwell
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1521: Kidney-Related Outcomes With Obinutuzumab in Patients With Active Lupus Nephritis: A Pre-Specified Exploratory Analysis of the Clinical Trial Data
Location: Hall F1
Abstract Poster Presenter: Brad Rovin, MD – The Ohio State University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1522: Outcomes of Continuing Hydroxychloroquine following Renal Transplant in Patients with Lupus Nephritis: A retrospective Cohort Study using the TrinetX database
Location: Hall F1
Abstract Poster Presenter: Carlos Pena, MD – Jefferson Einstein Philadelphia
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1523: Genetic architecture and translational insights for SLE progression from preclinical stages
1529: Updated Phase 1 Trial Data Assessing the Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of BMS-986353 (CC-97540), a CD19-directed Chimeric Antigen Receptor T Cell Therapy Using a Next-Generation Process for Severe, Refractory SLE
1530: The Renal Activity Index for Lupus Identifies and Predicts Complete Renal Remission or Absence of Kidney Involvement in Systemic Lupus Erythematosus
1531: Achieving Remission and Low Disease Activity with Belimumab versus Placebo in Patients with SLE Excluding the Glucocorticoid Component from Target Definitions: A Post Hoc Analysis of Five Phase 3 Trials
Location: Hall F1
Abstract Poster Presenter: Ioannis Parodis, MD, PhD – Karolinska Institutet and Karolinska University Hospital, Department of Medicine Solna, Division of Rheumatology
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1532: Preliminary Safety, Efficacy, and Cellular Kinetics of CTA313, a CD19/BCMA Dual-Targeted Universal CAR-T Therapy, for Active Systemic Lupus Erythematosus
1536: Evaluating Systemic Lupus Erythematosus Remission Among Patients Initiating Belimumab in a Real-World Setting in the USA
Location: Hall F1
Abstract Poster Presenter: Aarat Patel, MD – GSK, US Medical Affairs
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1537: Local Immune effector Cell-Associated Toxicity Syndrome (LICATS) in CAR T-cell treated patients with Autoimmune Disease
Location: Hall F1
Abstract Poster Presenter: Melanie Hagen, MD (she/her/hers) – Department of Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander-Universität (FAU) Erlangen-Nürnberg and Uniklinikum Erlangen
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1538: Safety, Pharmacodynamics, and Efficacy of a Novel Plasmacytoid Dendritic Cells Targeting Antibody in Healthy Adults and Patients with SLE or Cutaneous Lupus Erythematosus with Active Skin Lesions: A First-In-Human Study of KK4277
Location: Hall F1
Abstract Poster Presenter: Minoru Hasegawa, MD;PhD – Division of Medicine, University of Fukui
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1539: The Impact Of Interferon Signature On Anifrolumab Efficacy And Safety In Systemic Lupus Erythematosus: A Systematic Review And Meta-analysis
1541: Tofacitinib versus Belimumab in maintenance therapy of Systemic Lupus Erythematosus: A Real-World Study of the CSTAR cohort
Location: Hall F1
Abstract Poster Presenter: Qizhi Yuan, PhD – Peking Union Medical College
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1542: Alternative Definitions of Moderate Flares That Simulate Clinical Practice in Systemic Lupus Erythematosus: Post Hoc Exploration of Moderate Flares in Patients Treated with Dapirolizumab Pegol in a 48-week Phase 3 Trial
1545: Efficacy and Safety of Subcutaneous Anifrolumab in Systemic Lupus Erythematosus: Interim Analysis of a Phase 3 Randomized Placebo-controlled Study
1552: Treatment With Anifrolumab Prevents Long-Term Cardiovascular Damage Accrual Compared With Real-World Standard of Care in Patients With Systemic Lupus Erythematosus: Findings From the LASER Study
1555: Prevalence of Organ Involvement and Baseline Predictors of Disease Progression in Patients with Limited Cutaneous Systemic Sclerosis: Insights from the CONQUER Database
1556: Latent Profiles of Parenchymal Abnormalities and Vascular Features Measured by Quantitative CT Identifies a Subgroup of Systemic Sclerosis Patients With a Greater Lung Function Decline Over Time
1558: Gastrointestinal Symptom Severity Is Associated with Worse Patient-reported Outcomes and Dietary Patterns in Systemic Sclerosis: A Single Center Prospective Study
1570: Hydroxychloroquine and Disease Progression in Systemic Sclerosis: Insights from Antibody-Stratified Survival Analyses
Location: Hall F1
Abstract Poster Presenter: Francesco Bonomi, MD – University Hospital Careggi, Florence
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1571: Spatial Transcriptomics of Perivascular Subepidermal Regions in Very Early Systemic Sclerosis Unveils Cellular and Mitochondrial Stress-Driven Innate Immune Signatures that Initiate Stromal Remodeling
1572: Compromised intracellular oxygen availability and severe mitochondrial dysfunction in the skeletal muscle of patients with systemic sclerosis
Location: Hall F1
Abstract Poster Presenter: Tracy Frech, MD, MS – Vanderbilt University Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1573: WITHDRAWN
Location: Hall F1
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1574: A Rise in Serum KL-6 Levels Predicts Subsequent Progressive Pulmonary Fibrosis in Patients with Systemic Sclerosis-associated Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Keina Yomono, MD – Nippon Medical School
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1575: Clinical presentation, course, treatment and outcome of juvenile onset versus adult onset mixed connective tissue disease patients: a multicenter retrospective cohort.
Location: Hall F1
Abstract Poster Presenter: Kevin Chevalier – Université Paris Cité
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1576: Impact of COVID-19 Infection on Fibrosis Progression in CTD-Associated ILD: An AI-Based Quantitative CT Study
1577: Intravenous cyclophosphamide in the treatment of progressive interstitial lung diseases associated with systemic sclerosis: a prospective randomized trial versus placebo (SCLEROCYC).
Location: Hall F1
Abstract Poster Presenter: Luc Mouthon, MD, PhD – Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Cochin University Hospital, Université Paris Cité, AP-HP
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1578: Use of the CD19/CD3 T cell engager blinatumomab in refractory diffuse systemic sclerosis : a case series
1579: Exploring the Pulmonary Vascular Changes on Computed Tomography in predicting progression and mortality of Systemic Sclerosis-associated Interstitial Lung Disease
Location: Hall F1
Abstract Poster Presenter: Maria Iacovantuono, MD – Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1580: Lung Vasculature Quantification on Computed Tomography Predicts New Onset of Interstitial Lung Disease in Systemic Sclerosis
Location: Hall F1
Abstract Poster Presenter: Maria Iacovantuono, MD – Rheumatology, Allergology and Clinical Immunology, Department of Systems Medicine, Tor Vergata University, Rome, Italy
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1581: The Overall Prevalence and Associated Disease Characteristics of Calcinosis in Systemic Sclerosis: a Systematic Review and Meta-analysis
1582: Risk factors for incident digital ischemic complications in systemic sclerosis in the Collaborative National Quality and Efficacy Registry (CONQUER)
Location: Hall F1
Abstract Poster Presenter: Marissa Savoie, MD – Hospital for Special Surgery
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1583: Epidemiology, Outcome and Expenditures of Hospitalized Patients with Systemic Sclerosis: National Inpatient Sample 2021
1614: A Systematic Literature Review to Inform the EULAR Recommendations for the Management of Polymyalgia Rheumatica and Large Vessel Vasculitis: Focus on Referral and Diagnosis
1615: Prevalence of Clinical and Laboratory Manifestations of Patients with Deficiency of Adenosine Deaminase 2 (DADA2): A Systematic Review and Meta-Analysis
1617: Evaluating Familiarity and Knowledge Gaps in Polymyalgia Rheumatica Among Public Health Professionals
Location: Hall F1
Abstract Poster Presenter: Erik Stone, MA – Global Healthy Living Foundation
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1618: Use of JAK inhibitors in patients with refractory Takayasu arteritis: A worldwide retrospective study
Location: Hall F1
Abstract Poster Presenter: Fatma Alibaz-Oner, MD – MARMARA UNIVERSITY, SCHOOL OF MEDICINE, DEPARTMENT OF INTERNAL MEDICINE, DIVISION OF RHEUMATOLOGY
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1619: Systemic Immune-Inflammation Index Is Superior to Neutrophil-to-Lymphocyte Ratio for Assessing Disease Activity in Polymyalgia Rheumatica and Giant Cell Arteritis
1627: A Systematic Literature Review to Inform the 2025 EULAR Recommendations for Management of Polymyalgia Rheumatica and Large Vessel Vasculitis: Management of Disease Including Relapse and Complications
1628: Characterization of non-GCA, non-Takayasu Aortitis in a Single Health System Cohort
Location: Hall F1
Abstract Poster Presenter: Nuzhat Batool, MBBS – NYU Grossman Long Island School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1629: Real-World Effectiveness of Interleukin-6 Receptor Inhibitors Compared to Methotrexate in Steroid-Refractory Frail Patients with Polymyalgia Rheumatica
1630: Validation of the classification algorithm using the modified 2022 ACR/EULAR giant cell arteritis classification criteria and Japanese Takayasu arteritis diagnostic criteria
1637: Sleep Quality as a Modifier of the Relationship Between Physical Activity and Functional Limitation in Adults with or at High Risk of Knee Osteoarthritis
1642: The Impact of Secukinumab on Bone Density in Patients with Ankylosing Spondylitis: A 1-Year Retrospective Study
Location: Hall F1
Abstract Poster Presenter: Lemei An, MD – Henan Provincial People's Hospital, Zhengzhou University People's Hospital, Henan University People's Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1643: Optimizing Analyses of Chair Stand Test Outcome Data in the Multicenter Osteoarthritis Study: Exploration of Approaches to Handling Missing and/or Skewed Data with Performance-based Function Measures
Location: Hall F1
Abstract Poster Presenter: Michael LaValley, PhD – Boston University School of Public Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1644: Longitudinal Trajectory Models to Assess Pain and Risk of Difficult-to-Treat Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Misti Paudel, PhD, MPH – Brigham and Women's Hospital, Division of Rheumatology, Inflammation, and Immunity
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1645: A Sex-modified Association Between Perfluoroalkyl and Polyfluoroalkyl Substances (PFAS) Blood Concentration and Prevalent Arthritis Among Young and Middle-aged US Adults
1647: Clinical Phenotypes of Participants with Radiographic Osteoarthritis Attaining Patient Acceptable Symptom State in the Multicenter Osteoarthritis Study
1648: Predicting Worse Disease Activity, QOL, and Progression to Advanced Therapies at 12 and 24 months in Early RA: Results from the Canadian Early Arthritis Cohort (CATCH)
1067: Investigating Barriers to Care through Childhood Opportunity, Social Vulnerability, Area Deprivation, and Distance to Care in Pediatric Localized Scleroderma
1228: Transcending barriers to pain care in rural America: a pragmatic comparative effectiveness trial of evidence-based, on-demand, digital behavioral treatments for chronic pain
Location: Hall F1
Abstract Poster Presenter: Emily Holladay, MPH – University of Alabama at Birmingham
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1381: Self-Reported and Actigraphic Sleep and Circadian Rhythm Disruptions in Patients with Sjögren’s Disease: Associations with Disease Activity and Patient-Reported Outcomes
1610: Early Mepolizumab Initiation Enables High Glucocorticoid and Immunosuppressant Discontinuation Rates in EGPA: A Retrospective Cohort Study of 35 Patients
1066: Assessing Disparities in Outcomes and Processes of Care for Patients with Juvenile Idiopathic Arthritis in the Pediatric Rheumatology Care and Outcomes Improvement Network
Location: Hall F1
Abstract Poster Presenter: Julia Harris, MD – Children's Mercy Kansas City
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1123: Nanoencapsulated Sirolimus plus Pegadricase (NASP) Demonstrates Long Term Efficacy and Safety in Patients with Uncontrolled Gout: Results from the 24-week Double-blind Extension of the Phase 3 DISSOLVE I Study
Location: Hall F1
Abstract Poster Presenter: Alan Kivitz, MD, MACR – Altoona Center for Clinical Research
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1237: Six Month Clinical Outcomes of a Digital Therapeutic Augmented Virtual Care Clinic for Fibromyalgia Management
0929: SP2H, a Targeted Degrader of STimulator of INterferon Genes (STING), selectively inhibits STING-driven inflammation in vitro and in vivo and improves survival in Trex1-/- mice
1050: Bridging the Gap: A Mixed-Methods Study to Enhance Integration of HCQ-SAFE, A Shared Decision-Making Tool for Hydroxychloroquine Use, in Routine Lupus Care
Location: Hall F1
Abstract Poster Presenter: Shivani Garg, MD, PhD – University of Madison, School of Medicine and Public Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1077: Health literacy and work status in people with inflammatory arthritis: a cluster analysis in a national cohort
1126: Clinical Impact of Signs of Calcium Pyrophosphate Deposition Disease (CPPD) on Radiographs of Hands and Wrists in a Real-World Cohort of Patients with Early Rheumatoid Arthritis
1052: “prednisone… a Necessary Evil…” Developing an Evidence-based Benefits vs. Harms Shared Decision-making Tool (PRED-SAFE) to Support Decisions Around Chronic Prednisone Use
Location: Hall F1
Abstract Poster Presenter: Shivani Garg, MD, PhD – University of Madison, School of Medicine and Public Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1081: Insurance, Gender, and COVID-19’s Effects on Health Inequity in Rheumatoid Arthritis: A 12-Year Long Population Assessment
1143: Gout and Renal Failure-Related Mortality Trends in USA from 1999-2020: Analysis of CDC Wonder Database
Location: Hall F1
Abstract Poster Presenter: Shiamak Cooper, MD – Rochester General Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1144: A Quantitative Study of Renal Medulla Echogenicity in 250 Vietnames Gout Patients Shows Correlation with Poor Renal Function
Location: Hall F1
Abstract Poster Presenter: Thomas Bardin, MD – Lariboisiere Hospital, Department of Rheumatology
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1222: Efficacy of Fasinumab, An Anti-Nerve Growth Factor Monoclonal Antibody, in Managing Chronic Musculoskeletal Pain: A Systematic Review and Meta-Analysis
Location: Hall F1
Abstract Poster Presenter: Ahmed Abouelella, MBBCH – College of Human Medicine, Benha University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1342: The Impact of Age on Health-Related Quality of Life in Patients With Rheumatoid Arthritis Compared to Population Controls: A Cross-Sectional Analysis
Location: Hall F1
Abstract Poster Presenter: Saskia Truijen, MSc – Maastricht University Medical Centre+
1609: A Multicenter Prospective Longitudinal Observational Study to Determine Safety of Extended Treatment with Rituximab in Maintaining Remission in Patients with ANCA Associated Vasculitis (AAV) - An Interim Analysis
Location: Hall F1
Abstract Poster Presenter: Ravi Kumar U, DM – Christian Medical College
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0913: Potent and Selective Oral IRF5 Degrader, KT-579, Demonstrates In Vitro and In Vivo Activity Comparable or Superior to Approved or Clinically Active Agents in Human Cellular Assays and Lupus Efficacy Models
0923: Influenza Virus Infection Alters the MHC Class II Self-Immunopeptidome to Present Lupus-Associated Autoantigens
Location: Hall F1
Abstract Poster Presenter: Julia Rood, MD, PhD – Children's Hospital of Philadelphia
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0963: Increased expression of M2 pro-fibrotic markers in circulating monocytes and cultured monocyte-derived macrophages from systemic sclerosis patients with progressive interstitial lung disease (ILD)
Location: Hall F1
Abstract Poster Presenter: Emanuele Gotelli, MD, PhD – Laboratory of Experimental Rheumatology and Academic Division of Clinical Rheumatology, Department of Internal Medicine and Medical Specialties (Di.M.I.), University of Genova
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1054: Comedication Patterns of Romosozumab Early Adopters Among Medicare Enrollees: An Unsupervised Clustering Approach
Location: Hall F1
Abstract Poster Presenter: Ye Liu, MD, MPH, DrPH – University of Alabama at Birmingham
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1073: Development of a Culturally-Tailored Storytelling Intervention to Improve COVID-19 Vaccine Uptake in Black and Latinx Patients with Autoimmune and Inflammatory Rheumatic Diseases
0909: Loss of MicroRNA29 expression in B cells and skin microbiota synergize to promote atopic dermatitis in mice.
Location: Hall F1
Abstract Poster Presenter: Marcus Hines, MD;PhD – New York University Grossman School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0927: Improved Skin Lymphatic Flow Regulates Dendritic Cells to Mediate Lymph Node Fibroblast Alterations and Immune Responses in Lupus
Location: Hall F1
Abstract Poster Presenter: Mir Howlader, BA – Weill Cornell Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1062: Sex-related differences in clinical presentation and patient-reported burden in chronic back pain: Are these findings specific to axSpA? Results from the SHERPAS Cohort
1068: Association Between Social Determinants of Health Domains and covid-19-related Hospitalization in Individuals with Autoimmune Rheumatic Diseases: A Retrospective Analysis of National U.S. Data
0908: E-602 (Efgitasialase alfa) Enhances Memory B Cell Depletion and Reduces Profibrotic Macrophages via Desialylation in Autoimmune Disease
Location: Hall F1
Abstract Poster Presenter: Li Peng, PhD – Palleon Pharmaceuticals
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0933: Spatial Transcriptomics Reveal Altered Immune Dynamics Regulating Placental Development In a Humanized-TLR8 Mouse Model of Spontaneous Anti-Phospholipid Antibody Induced Pregnancy Loss
Location: Hall F1
Abstract Poster Presenter: Yunwei Xia, BA – Feinstein Institutes for Medical Research
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1129: Effectiveness of sodium-glucose cotransporter type 2 inhibitors and urate-lowering agents in patients with gout: data from a single-center specialised clinic
1395: A Comparative Study of Yao Syndrome and Primary Sjögren's Syndrome
Location: Hall F1
Abstract Poster Presenter: Nayaab Bakshi, DO – Stony Brook University Hospital
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1601: Obinutuzumab Induces and Maintains Remission in Refractory or Relapsing ANCA-Associated Vasculitis – A Case Series
Location: Hall F1
Abstract Poster Presenter: Helen Au, MBBS – Klinik für Innere Medizin, Rheumatologie und Immunologie, medius Klinik Kirchheim
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0906: Preclinical Characterization of IBI3034, an TACI and BCMA Chimeric Fc Fusion Protein, that Potently Modulates B Lymphocytes and Serum Immunoglobulin for the Treatment of B cell Related Autoimmune Disease
0910: Development of Four Distinct Human IgG4-Producing Mouse Models Recapitulating IgG4-Related Disease
Location: Hall F1
Abstract Poster Presenter: Min-Gang Kim, PhD – Seoul National University College of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0930: Potent and Selective Oral IRF5 Degrader, KT 579, Blocks Pro-Inflammatory Cytokines and Reduces Joint Swelling in a Mouse Model of Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Ryan Camire, PhD – Kymera Therapeutics
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1065: Age of Disease Onset and Risk of Serious Infection with Anti-tnf Use in Older Adults with Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Jiha Lee, MD, MHS – University of Michigan
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1137: Increased Risk of Cardiovascular Events and Mortality Related to Diffuse Idiopathic Skeletal Hyperostosis (DISH): A Systematic Review and Meta-Analysis
1044: Analysis of Medicare and Medicaid Utilization and Expenditure of Newly Approved Biologics for Systemic Lupus Erythematosus Patients in the United States
Abstract Poster Presenter: LEI LIU, MD – The Second Hospital affiliated to Zhejiang University, College of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1238: Pain Is Associated with An Increased Risk of Frailty in Veterans with Rheumatoid Arthritis
Location: Hall F1
Abstract Poster Presenter: Nadine El-ayache, DO, PhD – VA Puget Sound Health Care System & University of Washington
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1330: Sex and reproductive stage modify the role of endogenous estrogens on coronary atherosclerosis in rheumatoid arthritis and differences reflect effects on inflammation and cholesterol metabolism
1087: Impact of Neighborhood-Level Social Vulnerability on Disease Severity, Clinical Manifestations, and Early Mortality in Systemic Lupus Erythematosus
Location: Hall F1
Abstract Poster Presenter: Zoe Reed, MPH – Oklahoma Medical Research Foundation
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1139: Synovial Counts, Cultures, and Crystals: An Analysis of 9,000 Aspirations
1069: Strengthening Rheumatology Workforce Capacity and Impact on Patient Care in Louisiana: Expanding Fellowship Training Opportunities Through Strategic Partnerships
1063: Gender, Racial, and Geographic Trends in Mortality from Interstitial Lung Diseases Among Patients With Rheumatoid Arthritis in the U.S. Population, 1999–2020
Location: Hall F1
Abstract Poster Presenter: Farheen Malik, MD – Jacobi Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1127: The Pathogenetic Role of Calcium Pyrophosphate and Basic Calcium Phosphate Crystals in Osteoarthritis: Associations with Synovial Fluid Cytokines and Clinical Indices
1223: Pain and Fibromyalgia Across Autoimmune and Inflammatory Diseases in the AMP AIM Cohort
Location: Hall F1
Abstract Poster Presenter: Alexis Ogdie, MD – University of Pennsylvania
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1074: Racial Disparities in Cardiovascular, Ocular, and Treatment Outcomes in US Patients with Behçet’s Disease: A Propensity-Matched Real-World Analysis
1240: Serum Olink Proteomics Identifies Novel Mediators of Pain in Lupus Nephritis Patients Without Extrarenal Clinical Activity
Location: Hall F1
Abstract Poster Presenter: Philip Carlucci, MD – New York University School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1398: Reproductive Challenges and Cardiovascular Risks in Sjögren’s Syndrome and Systemic Sclerosis: A Meta-Analysis of Fertility, Pregnancy Outcomes, and Maternal Cardiac Health
1394: Burden of Comorbidities Across EULAR Sjögren’s Syndrome Disease Activity Index (ESSDAI) Domains: Treatment Prevalence Among Commercially Insured Sjögren’s Patients in the United States
1396: Influence of Age on Daily Impairment, Patient Empowerment, Activation and Engagement in Patients with Sjögren's Disease
Location: Hall F1
Abstract Poster Presenter: Nevsun Inanc, MD (she/her/hers) – Marmara University, School of Medicine, Department of Internal Medicine, Division of Rheumatology
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0907: Cross-Species Cellular Mapping and Humanization of Fcγ Receptors to Advance Antibody Modeling
0928: Radiolabelled anti-citrullinated histone antibody CIT-013 as a tool to visualize NET rich inflamed joints in a collagen induced arthritic mouse model
1611: Effectiveness of Avacopan and Its Impact on Serum Calprotectin in MPA/GPA Patients Receiving Rituximab-Based Remission Induction: A Single-Center Study
Location: Hall F1
Abstract Poster Presenter: Yusuke Ushio, MD – Division of Hematology, Rheumatology and Respiratory Medicine, Department of Internal Medicine, Faculty of Medicine, Kagawa University
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1056: High diagnostic rate of genetic testing in adult patients with autoinflammation: A Single Center Experience
1402: Understanding Fatigue Through Patients' Eyes: Development of a Novel Questionnaire Capturing the Complexity of Real-Life Fatigue in Sjögren's Disease
Location: Hall F1
Abstract Poster Presenter: Saviana Gandolfo, MD – Rheumatology Unit, Ospedale del mare, Naples
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1379: Renal tubular acidosis in Sjögren’s disease and non-Sjögren’s sicca in an Oklahoma cohort
Location: Hall F1
Abstract Poster Presenter: Biji T Kurien, PhD – Oklahoma Medical Research Foundation
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0904: SLAMF7 Drives Plasma Cell Differentiation in Rheumatoid Arthritis Synovium.
0918: Retention of variant forms of TNFR1 in the Golgi induces stress responses and monocyte activation in systemic Juvenile Idiopathic Arthritis (sJIA)
Location: Hall F1
Abstract Poster Presenter: Anthony Cruz, BS – National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), NIH
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1048: Impact of Hydroxychloroquine Usage on QTc in Veterans with Rheumatic Musculoskeletal Disease
1061: Screening for Hepatitis B in a Veterans Health Administration Subpopulation with Rheumatological Disease Prior to Initiating Immunosuppressive Therapy: a retrospective study on testing and treatment within the Black American population from the VAMC in Memphis, TN
1236: Vestibulocortical Stimulation via Caloric Irrigation in Nociplastic Disease: Therapeutic Effects on Pain, Autonomic Functioning & Quality of Life Measures
Location: Hall F1
Abstract Poster Presenter: Michael Kaplan, MD – Icahn School of Medicine at Mount Sinai
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1387: Demographic and Clinical Characteristics of Patients Diagnosed With Sjögren’s Disease Using Electronic Health Records and Linked Claims Data From the US Excellence Network in RheumatoloGY (ENRGY) Practice-Based Research Network
1603: SGLT-2 Inhibitors are Associated with Lower Risk of End Stage Renal Disease (ESRD) and Lower Mortality in ANCA-associated Vasculitis With Kidney Involvement
Location: Hall F1
Abstract Poster Presenter: Julia Foos, BA – University of Toledo College of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
0915: A Fusion of TACI Variant and Anti-ifnar Antibody with Greater Therapeutic Effect on Related Autoimmune Disease Models
1245: Efficacy And Safety of Low-dose Naltrexone In Fibromyalgia: An Updated Systematic Review And Meta-Analysis of Randomized Controlled Trials (RCTs)
Location: Hall F1
Abstract Poster Presenter: Rubab Rizwan, MD – VBMC,Nuvance Health
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1390: Cystic Lung Disease and Autoantibodies in Lymphocytic Interstitial Pneumonia: Exploring the Impact of Sjögren’s Syndrome
1136: The Impact of Iron Overload and HFE Genetic Mutations on Joint Disease in Haemochromatosis: Data from the Haemochromatosis Arthropathy Inception Cohorts
1047: Primary Care Perspectives on Giant Cell Arteritis: Diagnostic Considerations, Referral Challenges, and Opportunities for Fast-Track Pathways in the U.S.
Location: Hall F1
Abstract Poster Presenter: Jon Golenbiewski, DO – Wake Forest University School of Medicine
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1055: The Price of Relief: Examining the Role of Insurance in High-Cost Medication Use
1138: Efficacy of Pozdeutinurad (AR882) in Treatment Naïve and Suboptimally Treated Gouty Arthritis with Tophi
Location: Hall F1
Abstract Poster Presenter: Robert Keenan, MD – Arthrosi Therapeutics
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1242: Relax the Body: Dual-Agent Nighttime Therapy for Fibromyalgia: Symptom Reduction Using Tricyclic Antidepressants and Muscle Relaxants
Location: Hall F1
Abstract Poster Presenter: Robert Katz, MD – Rush University Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1384: Systematic Review of Therapies for Central Nervous System Manifestations in Sjögren’s Disease
Location: Hall F1
Abstract Poster Presenter: Ghaith Noaiseh, MD – University of Kansas Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1594: Two-Year Efficacy of Anti-Interleukin-5/Receptor Therapies According to Anti-Neutrophil Cytoplasmic Antibodies Status in Patients with Eosinophilic Granulomatosis with Polyangiitis
0919: Proteomic Profiling of Extracellular Vesicles from Synovial Fluid of RA and OA Patients Reveals Cell-type-specific subpopulations and Disease Related Patterns
1041: Associated Factors and Direct Cost Analysis of Dose Reduction and Discontinuation of Biological Therapies in Rheumatoid Arthritis and Spondyloarthritis: Findings from a Colombian Cohort Within the Framework of an Integrated Management Model
0921: Fibrinogen Co-Modified with Malondialdehyde-Acetaldehyde and Citrulline Promotes Pro-Inflammatory Macrophage Differentiation Through p38 and NF-κB Signaling
Location: Hall F1
Abstract Poster Presenter: Hannah Johnson, BS – University of Nebraska Medical Center
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1042: Biosimilar adalimumab prescriptions increase before the CVS formulary change and decrease after
Location: Hall F1
Abstract Poster Presenter: Eric Roberts, PhD, MPH – University of California, San Francisco
Monday, Oct 27th
10:30 AM - 12:30 PM Central Time
1070: Cervical Cancer and HPV Screening in Women with Lupus vs Healthy Control Group: A Retrospective Study at a Tertiary Referral Center
1386: Characterization and Progression of Localized Amyloidosis in Sjogren’s Syndrome: Evidence Long-Term (1995-2025) Follow-Up of a Cohort compared to Literature Review.
